Recommendations for the measurement of the most important plasma proteins;Indicazioni per la misura delle principali proteine sieriche

Biochimica Clinica

Volumn 36, Issue 4, 2012, Pages 244-267

  Graziani, Maria Stella ^a   Caldini, Anna ^b   Basile, Umberto ^c   Dolci, Alberto ^d   Ferraro, Simona ^d   Ferrarotti, Ilaria ^e   Infusino, Ilenia ^d   Muratore, Maria Teresa ^g   Mussap, Michele ^h   Obici, Laura ^f   Pezzati, Paola ^b   Previtali, Giuseppe ⁱ   Szoke, Dominika ^d   Terreni, Alessandro ^b   Zaninotto, Martina ^j   Merlini, Giampaolo ^f  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e Centro di Riferimento per la Diagnosi Del Deficit Ereditario di a1 Antitripsina   (Italy)

^f FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^g BELCOLLE HOSPITAL   (Italy)

^h UNIVERSITY OF GENOA   (Italy)

ⁱ Azienda Unità Sanitaria Locale di Parma   (Italy)

^j UNIVERSITY HOSPITAL OF PADOVA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA 1 ANTITRYPSIN; ALPHA 2 MACROGLOBULIN; BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; CERULOPLASMIN; COMPLEMENT FACTOR; CYSTATIN C; FERRITIN; HAPTOGLOBIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; OROSOMUCOID; PLASMA PROTEIN; PREALBUMIN; RHEUMATOID FACTOR; SERUM AMYLOID A; TRANSFERRIN; TRANSFERRIN RECEPTOR;

CERULOPLASMIN BLOOD LEVEL; COCHRANE LIBRARY; FERRITIN BLOOD LEVEL; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MEASUREMENT; MEDICAL SOCIETY; MEDLINE; META ANALYSIS (TOPIC); PRACTICE GUIDELINE; PROTEIN BLOOD LEVEL; REVIEW; SYSTEMATIC REVIEW (TOPIC); TRANSFERRIN BLOOD LEVEL;

EID: 84867359237     PISSN: 03930564     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (132)

1. Lothar T. Proteins in clinical and laboratory medicine. Frankfurt, GE: TH-Books Verlaggesellschaft, 2008.
2. Friedman AN, Fadem SZ. Reassessment of albumin as nutrition marker in kidney disease. J Am Soc Nephrol 2010;21:223-30.
3. Rothschild MA, Oratz M, Schreiber SS. Albumin synthesis. N Eng J Med 1972;286:816-21.
4. Fleck A, Raines G, Hawker F, et al. Increased vascular permeability: a major cause of hypoalbuminemia in disease and injury. Lancet 1985;8432:781-4. (Pubitemid 15111938)
5. Liumbruno G, Bennardello F, Lattanzio A, et al. Raccomandazioni SIMTI sul corretto utilizzo degli emocomponenti e dei plasma derivati. Raccomandazioni per l'uso dell'albumina. Milano. Società Italiana di Medicina Trasfusionale e Immunoematologia (SIMTI) ed., 2008:45-58.
6. Alderson P, Bunn F, Li Wan Po A, et al. Human albumin solution for resuscitation and volume expansion in critically ill patients. Cochrane Database Syst Rev 2004;18:CD001208.
7. European Best Practice Guidelines for Haemodialysis. Nephrol Dial Transplant 2002;17(suppl 7):1-111.
8. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol 2005;23:3412-20.
9. Dimopoulos M, Kyle R, Fermand JP, et al. Guidelines for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood 2011;117:4701-5.
10. Wiedermann CJ, Wiedermann W, Joannidis M. Hypoalbuminemia and acute kidney injury: a meta-analysis of observational clinical studies. Intensive Care Med 2010;36:1657-65.
11. Gooptu B, Ekeowa UI, Lomas DA. Mechanisms of emphysema in alpha1-antitrypsin deficiency molecular and cellular insights. Eur Respir J 2009;34:475-88.
12. Ferrarotti I, Thun GA, Zoezetto M, et al. Serum levels and genotype distribution of g1-antitrypsin in the general population. Thorax 2012 10.1136/thoraxjnl-2011-201321.
13. Ferrarotti I, Torrini M, Scabini R, et al. Diagnosi di laboratorio del deficit ereditario di g1-antitripsina. Biochim Clin 2009;33:39-44.
14. Silverman EK, Sandhaus RA. α1-antitrypsin deficiency. N Engl J Med 2009;360:2749-57.
15. Miravitles M, Herr C, Ferrarotti I, et al. Laboratory testing of individuals with severe α1-antitrypsin deficiency in three European centres. Eur Respir J 2010;35:960-8.
16. American Thoracic Society/European Respiratory Society Statement: Standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 2003;168:818-900.
17. Fournier T, Medjoubi-N N, Porquet D. Alpha-1-acid glycoprotein. Biochim Biophys Acta 2000;1482:157-71.
18. Chu CT, Howard GC, Misra UK, et al. Alpha2-macroglobulins: a sensor for proteolysis. Ann N Y Acad Sci 1994;10:291-307.
19. Dodel RC, Du Y, Bales KR, et al. Alpha2-macroglobulin and the risk of Alzeimer's disease. Neurology 2000;25:438-42.
20. Gangadharan B, Antrobus R, Dwek RA, et al. Novel serum biomarker candidates for liver fibrosis in hepatitis C patients. Clin Chem 2007;53:1792-9. (Pubitemid 47509672)
21. Jeppsson JO. Haptoglobin. In: Ritchie RF, Navolotskaia O, eds. Serum proteins in clinical medicine. Scarborough: Foundation for Blood Research, 1996:7.04-1-6.
22. Tabbara IA. Hemolitic anemias. Diagnosis and treatment. Med Clin North Am 1992;76:649-68.
23. Dhaliwal G, Cornett PA, Tierney LM. Hemolitic anemia. Am Fam Physician 2004;69:2599-606.
24. Marchand A, Galen RS, van Lente F. The predictive value of serum haptoglobin in haemolytic disease. JAMA 1980;243:1909-11. (Pubitemid 10094689)
25. Berggård I, Bearn AG. Isolation and properties of a low molecular weight β2-globulin occurring in human biological fluids. J Biol Chem 1968;243:4095-103.
26. Kyle RA, Durie BGM, Rajkumar SV, at al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010;24:1121-7.
27. Nikhil C, Munshi C, Anderson P, et al. Guidelines for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood 2011;117:4696-700.
28. Khouri IF, Saliba RM, Okoroji GJ, et al. Long term follow up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission. Cancer 2003;98:2630-5.
29. Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2: A new prognostic index for follicular lymphoma developed by the International Follicular Lymphoma Prognostic Factors Project. J Clin Oncol 2009;27:4555-62.
30. Kim HA, Jeon JY, Yoon JM, et al. Beta 2-microglobulin can be a disease activity marker in systemic lupus erythematosus. Am J Med Sci 2010;339:337-40.
31. Elefsiniotis IS, Moulakakis A, Pantazis KD, et al. Relationship between serum beta-2-microglobulin levels and virological breakthrough in HBeAg negative chronic hepatitis B patients, under long-term treatment schedules including lamivudine. World J Gastroenterol 2005;11:1922-8. (Pubitemid 40520987)
32. Davey PG, Gosling P. Beta 2-microglobulin instability in pathological urine. Clin Chem 1982;28:1330-3. (Pubitemid 12125066)
33. Katzmann JA, Clark RJ, Abraham RS, et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 2002;48:1437-44. (Pubitemid 34925779)
34. Albertini R, Merlini G. La misura delle catene leggere libere delle immunoglobuline nel siero: aspetti analitici e clinici. Biochim Clin 2010;34:26-9.
35. Te Velthuis H, Knop I, Stam P, et al. N Latex FLC - new monoclonal high performance assays for the determination of free light chain kappa and lambda. Clin Chem Lab Med 2011;49:1323-32.
36. Dolci A, Vernocchi A. Aspetti metodologici per la ricerca e la caratterizzazione delle componenti monoclonali nel siero. Biochim Clin 2012;36:84-8.
37. Dispenzieri A, Kyle RA, Merlini GP, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009;23:215-24.
38. Bird J, Behrens J, Westin J, et al. UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected Mproteins and the management fo monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol 2009;147:22-42.
39. Berenson JR, Anderson KC, Audell RA, et al. Monoclonal gammopathy of undetermined significance: a consensus statement. Br J Haematol 2010;150:28-38.
40. Hutchison CA, Cook M, Heyne N, et al. European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): a randomised control trial. Trials 2008;9:55.
41. Durie BG, Harousseau JL, Miguel JS, et al. on behalf of the International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467-73. (Pubitemid 44264086)
42. Koschinsky ML, Funk WD, Van Oost BA, et al. Complete cDNA sequence of human preceruloplasmin. Proc Natl Acad Sci USA 1986;83:5086-90. (Pubitemid 16051321)
43. Hellman N, Gitlinn J. Ceruloplasmin metabolism and function. Annu Rev Nutr 2002;22:439-58. (Pubitemid 35221468)
44. Roberts EA, Schilsky MI. Diagnosis and treatment of Wilson Disease: An update. Hepatology 2008;47:2089-111. (Pubitemid 351945575)
45. Mak CM, Lam CW. Diagnosis and treatment of Wilson's Disease: A conprehensive review. Crit Rev Clin Lab Sci 2008;45:263-90. (Pubitemid 351883129)
46. EASL Clinical Practice Guidelines: Wilson's disease. European Association for Study of Liver. J Hepatol 2012;56:671-85.
47. Kaler SG. Diagnosis and therapy of Menkes syndrome, a genetic form of copper deficiency. Am J Clin Nutr 1998;67:1029S-34S. (Pubitemid 28198828)
48. Mussap M, Plebani M. Biochemistry and clinical role of human cystatin C. Crit Rev Clin Lab Sci 2004;41:467-550. (Pubitemid 39488773)
49. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as marker of kidney function: a meta-analysis. Am J Kidney Dis 2002;40:221-6. (Pubitemid 34827638)
50. Roos JF, Doust J, Tett SE, et al. Diagnostic accuracy of cystatin C compared to serum creatinine for the estimation of renal dysfunction in adults and children: a meta-analysis. Clin Biochem 2007;40:383-91.
51. Chew JS, Saleem M, Florkowski CM, et al. Cystatin C. A paradigm of evidence based laboratory medicine. Clin Biochem Rev 2008;29:47-62.
52. Bagshaw SM, Bellomo R. Cystatin C in acute kidney injury. Curr Opin Crit Care 2010;16:533-9.
53. http://www.renal.org/clinical/GuidelinesSection/AcuteKidneyInjury.aspx
54. Taglieri N, Koenig W, Kaski JC. Cistatina C e rischio cardiovascolare. Biochim Clin 2011;35:46-55.
55. Ghidoni R, Benussi L, Glionna M, et al. Plasma cystatin C and risk of developing Alzheimer's disease in subjects with mild cognitive impairment. J Alzheimer Dis 2010;22:985-91.
56. Dorner T, Hansen A. Autoantibodies in normals: the value of predicting rheumatoid arthritis. Arthritis Res Ther 2004;6:282-4.
57. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569-81.
58. Rheumatoid arthritis. The management of rheumatoid arthritis in adults. www.nice.org.uk/CG79
59. Chatzidionysiou K, Lie E, Nasonov E, et al. Highest clinical effectivenss of rituximab in autoantibody-positive patients with rheumatoid arthritis: pooled data from 10 European registries. Ann Rheum Dis 2011;70:1575-80.
60. Finch CA, Bellotti V, Stray S, et al. Plasma ferritin determination as a diagnostic tool. West J Med 1986;145:657-63. (Pubitemid 17196113)
61. Guyatt GH, Oxman AD, Ali M, et al. Laboratory diagnosis of iron-deficiency anemia: an overview. J Gen Intern Med 1992;7:145-53.
62. Knovich MA, Storey JA, Coffman LG, et al. Ferritin for the clinician. Blood Rev 2009;23:95-104.
63. Means RT Jr, Allen J, Sears DA, et al. Serum soluble transferrin receptor and the prediction of marrow aspirate iron results in a heterogeneous group of patients. Clin Lab Haematol 1999;21:161-7. (Pubitemid 29327337)
64. Suominen P, Möttönen T, Rajamäki A, et al. Single values of serum transferrin receptor and transferrin receptor ferritin index can be used to detect true and functional iron deficiency in rheumatoid arthritis patients with anemia. Arthritis Rheum 2000;43:1016-20. (Pubitemid 30368178)
65. Rimon E, Levy S, Sapir A, et al. Diagnosis of iron deficiency anemia in the elderly by transferring receptor-ferritin index. Arch Intern Med 2002;162:445-9. (Pubitemid 34150647)
66. Mast AE, Blinder MA, Lu Q, et al. Clinical utility of the reticulocyte hemoglobin content in the diagnosis of iron deficiency. Blood 2002;99:1489-91. (Pubitemid 34547111)
67. Fernández-Rodríguez AM, Guindeo-Casasús MC, Molero-Labarta T, et al. Diagnosis of iron deficiency in chronic renal failure. Am J Kidney Dis 1999;34:508-13. (Pubitemid 29413624)
68. Intragumtornchai T, Rojnukkarin P, Swasdikul D, et al. The role of serum ferritin in the diagnosis of iron deficiency anaemia in patients with liver cirrhosis. J Intern Med 1998;243:233-41. (Pubitemid 28238016)
69. KDOQI. Clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007;50:476-530.
70. Schmitt B, Golub RM, Green R, et al. Screening primary care patients for hereditary hemochromatosis with transferrin saturation and serum ferritin level: systematic review for the American College of Physicians. Ann Intern Med 2005;143:522-36.
71. European Association for the Study of the Liver. EASL clinical practice guidelines for HFE hemochromatosis. J Hepatol 2010;53:3-22.
72. Crawford DH, Murphy TL, Ramm LE, et al. Serum hyaluronic acid with serum ferritin accurately predicts cirrhosis and reduces the need for liver biopsy in C282Y hemochromatosis. Hepatology 2009;49:418-25.
73. Di Bisceglie AM, Axiotis CA, Hoofnagle JH, et al. Measurements of iron status in patients with chronic hepatitis. Gastroenterology 1992;102:2108-13.
74. Geha RS, Notarangelo LD, Casanova GL, et al. Primary immunodeficiency diseases: An update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee. J Allergy Clin Immunol 2007;120:776-94.
75. de Vries E, Dreiessen G. Primary immunodeficiencies in children: a diagnostic challenge. Eur J Pediatr 2011;170:169-77.
76. Yel L. Selective IgA deficiency. J Clin Immunol 2010;30:10-6.
77. European Association for the Study of the Liver. EASL clinical practice guidelines: management of cholestatic liver diseases. J Hepatol 2009;51:237-67.
78. Behrens BJ, Westin J, Turesson I, et al. UK Myeloma forum (UKMF), and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol 2009;147:22-8.
79. Karen DF, Jeffrey S, Warren JS, et al. Strategy to diagnose monoclonal gammopathies in serum: high-resolution electrophoresis, immunofixation, and κ,λquantification. Clin Chem 1988;34:2196-201. (Pubitemid 19001233)
80. Bianchi P, McNamara E, Bergami MR, et al. Immunochemical evaluation of monoclonal gammopathies. Heavy chain to light chain ratio is of little practical value for detecting IgD myelomas and free light chains. Clin Chem 1992;38:317-9.
81. American Gastroenterology Association: Institute Medical Position Statement on the diagnosis and management of celiac disease. Gastroenterology 2006;131:1977-80.
82. Chen K, Cerutti A. New insight into the enigma of immunoglobulin D. Immunol Rev 2010;237:160-79.
83. Ammouri W, Cuisset L, Rouage S, et al. Diagnostic value of serum immunoglobulinaemia D level in patients with a clinical suspicion of hyper IgD syndrome. Rheumatology 2007;46:1597-600. (Pubitemid 47500578)
84. Szalai AJ, Agrawal A, Greenhough TJ, et al. C-reactive protein: structural biology and host defense function. Clin Chem Lab Med 1999;37:265-70. (Pubitemid 29209739)
85. Kushner I, Gewurz H, Benson MD. C-reactive protein and acute phase response. J Lab Clin Med 1981;97:739-49. (Pubitemid 11111474)
86. Schultz DR, Arnold PI. Properties of four acute phase proteins: C-reactive protein, serum-amyloid A protein, α1 acid-glycoprotein and fibrinogen. Semin Arthritis Rheumatism 1990;86:129-47.
87. Colley CM, Fleck A, Goode AW, et al. Early time course of the acute phase response in man. J Clin Pathol 1983;36:1203-7.
88. Simon L, Gauvin F, Amre DK, et al. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 2004;39:206-17. (Pubitemid 38971491)
89. Emery P, Gabay C, Kraan M, et al. Evidence-based review of biologic markers as indicators of disease progression and remission in rheumatoid arthritis. Rheumatol Int 2007;27:793-806. (Pubitemid 46906651)
90. Stange EF, Travis SPL, Vermeire S, et al. European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohns Colitis 2008;2:1-23. (Pubitemid 351179487)
91. Van Assche G, Dignass A, Panes J, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. J Crohns Colitis 2010;4:7-27.
92. Heikkilä K, Ebrahim S, Lawlor DA. A systematic review of the association between circulating concentrations of C-reactive protein and cancer. J Epidemiol Community Health 2007;61:824-32. (Pubitemid 47311721)
93. Lowe P, Metzger BE, Lowe WL jr, et al. Inflammatory mediators and glucose in pregnancy: results from a subset of the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study. J Clin Endocrinol Metab 2010;95:5427-34.
94. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice. A statement for healthcare professional from the Centers for DiseaseControl and Prevention and American Heart Association. Circulation 2003;107:499-511. (Pubitemid 36158056)
95. Pearson TA, Bazzarre TL, Daniels SR, et al. American Heart Association guide for improving cardiovascular health at the community level: a statement for public health care practitioners, health providers and health policy makers from the American Heart Association Expert Panel on Population and Prevention Science. Circulation 2003;107:645-51. (Pubitemid 36176819)
96. Myers GL, Rifai N, Tracy RP, et al. CDC/AHA workshop on markers of inflammation and cardiovascular disease: application to clinical and health public practice. Report from the laboratory science discussion group. Circulation 2004;110:e545-9.
97. Myers GL, ed. National Academy of Clinical Biochemistry. Laboratory Medicine Practice Guidelines. Emerging biomarkers for primary prevention of cardiovascular disease and stroke. Washington DC: American Association for Clinical Chemistry, 2009.
98. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004;350:1387-97. (Pubitemid 38419992)
99. Ridker PM, Buring JE, Rifai N, et al. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 2007;297:611-9.
100. Ridker PM, MacFayden J, Libby P, et al. Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER). Am J Cardiol 2010;106:204-9.
101. Pepys MB, Hirschfield GM, Tennent GA, et al. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 2006;440:1217-21.
102. Frey SK, Nagl B, Henze A, et al. Isoforms of retinol binding protein 4 (RBP4) are increased in chronic diseases of the kidney but not of the liver. Lipids Health Dis 2008;7:29.
103. Nutritional management of cystic fibrosis. UK Cystic Fibrosis Trust. Nutrition Working Group 2002 http://www.cftrust.org.uk/aboutcf/publications/ consensusdoc/
104. Tanumihardjo SA. Assessing vitamin A status: past, present and future. J Nutrition 2004;134:290S-3S. (Pubitemid 38057465)
105. Fujïta M, Brindle R, Rocha A, et al. Assessment of the relative dose-response test based on serum retinolbinding protein instead of serum retinol in determining low hepatic vitamin A stores. Am J Clin Nutr 2009;90:217-24.
106. Drescher T, Singler K, Ulrich A, et al. Comparison of two malnutritional risk screening methods (MNA and NRS 2002) and their association with markers of protein malnutrition in geriatric hospitalized patients. Eur J Clin Nutr 2010;64:887-93.
107. Koch A, Weiskirchen R, Sanson E, et al. Circulating retinol binding protein 4 in critically hill patients before specific treatment: prognostic impact and correlation with organ function, metabolism and inflammation. Crit Care 2010;14:R179.
108. Duntas RH, Biondi D. New insight into subclinical hypothyroidism and cardiovascular risk. Semin Thromb Hemostas 2011;37:27-34.
109. Speeckaert MM, Speeckaert R, Delanghe JR. Biological and clinical aspects of soluble transferrin receptor. Crit Rev Clin Lab Sci 2011;47:213-28.
110. Skikne B. Serum transferrin receptor. Am J Hematol 2008;83:872-5.
111. Skikne B, Punnonen K, Caldron PH, et al. Improved differential diagnosis of anemia of chronic disease and iron deficiency anemia: A prospective multicenter evaluation of soluble transferrin receptor and the sTfR/log ferritin index. Am J Hematol 2011;86:923-7.
112. Koulaouzidis A, Said E, Cottier R, et al. Soluble transferrin receptors and iron deficiency, a step beyond ferritin. A systematic review. J Gastrointestin Liver Dis 2009;18:345-52.
113. Yamada T. SAA: review of biology, assay methods and clinical usefulness. Clin Chem Lab Med 1999;37:381-8. (Pubitemid 29218956)
114. Obici L, Donadei S, Albertini R, et al. Siero amiloide A e flogosi. Biochim Clin 2010;34:326-30.
115. Lachmann HJ, Goodman HJ, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. New Engl J Med 2007;356:2361-71. (Pubitemid 46883770)
116. Mosca M, Tani C, Aringer M, et al. European League Against Rheumatism. Recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis 2010;69:1269-74.
117. Dammaco F, Sansonno D, Piccoli C, et al. The cryoglobulin: an overview. Eur J Clin Invest 2001;31:628-38.
118. Zuraw BL, Christiansen SC. Pathogenesis and laboratory diagnosis of hereditary angioedema. Allergy Asthma Proc 2009;30:487-92.
119. National Clinical Guideline Centre. Anaemia management in chronic kidney disease. Rapid update 2011. NICE Clinical Guidelines No. 114. National Clinical Guideline Centre (UK). London: Royal College of Physicians (UK), 2011.
120. Milman N, Albeck MJ. Distinction between homozygous and heterozygous subjects with hereditary haemochromatosis using iron status markers and receiver operating characteristic (ROC) analysis. Eur J Clin Chem Clin Biochem 1995;33:95-8.
121. Murtagh LJ, Whiley M, Wilson S, et al. Unsaturated iron binding capacity and transferrin saturation are equally reliable in detection of HFE hemochromatosis. Am J Gastroenterol 2002;97:2093-9.
122. Thorstensen K, Kvitland MA, Irgens WO, et al. Screening for C282Y homozygosity in a Norwegian population (HUNT2): The sensitivity and specificity of transferrin saturation. Scand J Clin Lab Invest 2010;70:92-7.
123. Ingbar SH. Pre-albumin: a thyroxin binding protein of human plasma. Endocrinology 1958;63:256-9.
124. Monaco HL. The transthyretin-retinol-binding protein complex. Biochim Biophys Acta 2000;1482:65-72.
125. Ritchie RF, Palomaki GE, Neveux LM, et al. Reference distributions for the negative acute-phase serum proteins, albumin, transferrin and transthyretin: a practical, simple and clinically relevant approach in a large cohort. J Clin Lab Anal 1999;13:273-9.
126. Johnson AM, Merlini G, Sheldon J, et al. Clinical indications for plasma protein assays: transthyretin (prealbumin) in inflammation and malnutrition. International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Scientific Division Committee on Plasma Proteins (C-PP). Clin Chem Lab Med 2007;45:419-26. (Pubitemid 46480890)
127. Johnson AM, Merlini G, Sheldon J, et al. La transtiretina (prealbumina) nella infiammazione e malnutrizione. Biochim Clin 2007;31:97-104.
128. Suyama Y, Adachi K, Notsu Y, et al. Efficacy of corrected rapid turnover protein increment index (CRII) for early detection of improvement of nutrition status in patients with malnutrition. J Clin Biochem Nutr 2009;45:44-8.
129. Molnar MZ, Keszei A, Cizra ME, et al. Evaluation of the malnutrition-inflammation score in kidney transplant recipients. Am J Kidney Dis 2010;56:102-11.
130. Fiedler R, Jehle PM, Onsten B, et al. Clinical nutrition scores are superior for the prognosis of haemodialysis patients compared to lab markers and bioelectrical impedance. Nephrol Dial Transplant 2009;24:3812-7.
131. Caporali R, Caccialanza R, Bonino C, et al. Disease-related malnutrition in outpatients with systemic sclerosis. Clinical Nutrition 2012: doi:10.1016/j.clnu.2012.02.010
132. Herselman M, Esau N, Kruger JM, et al. Relationship between serum protein and mortality in adults on long-term hemodyalisis: exhaustive review and meta-analysis. Nutrition 2010;26:10-32.